Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Current Leases (2021 - 2025)

Pliant Therapeutics (PLRX) has disclosed Current Leases for 5 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases rose 166.97% to $1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 million, a 166.97% increase, with the full-year FY2025 number at $1.4 million, up 166.97% from a year prior.
  • Current Leases was $1.4 million for Q4 2025 at Pliant Therapeutics, up from $1.2 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.6 million in Q3 2022 to a low of $98000.0 in Q2 2024.
  • A 5-year average of $1.5 million and a median of $1.4 million in 2025 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: tumbled 95.61% in 2024, then surged 1150.0% in 2025.
  • Pliant Therapeutics' Current Leases stood at $1.9 million in 2021, then soared by 31.46% to $2.5 million in 2022, then crashed by 46.36% to $1.3 million in 2023, then plummeted by 58.88% to $542000.0 in 2024, then surged by 166.97% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Current Leases are $1.4 million (Q4 2025), $1.2 million (Q3 2025), and $1.2 million (Q2 2025).